- CEO
- Chun Ming Gao
- Full Time Employees
- 3,514
- Sector
- Finance
- Industry
- Real estate development
- Address
- No. 888, High-tech Zone Jinan SD China 250101
- IPO Date
- Jan 13, 2000
- Business
- Lushang Freda Pharmaceutical Co., Ltd. (600223.SS) is a China-based company primarily engaged in the research, development, production, and sale of pharmaceuticals and cosmetics. The company offers a broad portfolio of products, including Chinese patent medicines, chemical medicines, and health foods across orthopedics, gynecology, internal medicine, ophthalmology, and pediatrics; cosmetics such as cleansers, lotions, creams, essences, and masks under brands like Yilian (Lotus Care), Aier Boshi (Dr. Alva), Yipaerhan (Ile Fragrance), Mingren, Runjie, and Special; active pharmaceutical ingredients (APIs), medical devices, health supplements, and functional foods; as well as synthetic biological materials like hyaluronic acid (HA), where it leads China's industry, food additives including Natamycin and Nisin, and natural cosmetic ingredients such as Ectoin, Sodium Polyglutamate, and Pullulan.
Founded in 1993 and headquartered in Jinan, Shandong Province, China, the company operates seven specialized production bases in Jinan, Linyi, Jining, and Yili (Xinjiang), with products distributed to over 70 countries in North America, the European Union, Japan-Korea, and Southeast Asia.
It maintains subsidiaries and operates as a subsidiary of Shandong Freda Biological Co., Ltd., with a strong emphasis on innovation through four national-level R&D platforms, 17 provincial facilities, and collaborations with institutions like Zhejiang University and the Shanghai Institute of Materia Medica.
In recent developments, the company reported first-half 2025 revenue of CNY 1.79 billion, down 7.1% year-over-year, with net profit attributable to shareholders at CNY 108 million, down 15.2%, reflecting steady growth in the Yilian brand amid adjustments to the Aier Boshi brand. It announced plans to divest its wholly-owned subsidiary Shandong Lushang Inzone Commercial Management for approximately CNY 88.4 million in October 2025, focusing on core pharmaceutical and cosmetics operations. Additionally, in February 2024, it sold an equity interest in Daantong to Lushang Life Services Co., Ltd. as part of portfolio streamlining.